References
1. Chibber P, Haq SA, Ahmed I, Andrabi NI, Singh G. Advances in the possible treatment of COVID-19: A review. European journal of pharmacology. 2020 Jul 16:173372.
2. Zhang XY, Huang HJ, Zhuang DL, Nasser MI, Yang MH, Zhu P, et al. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2. Infectious diseases of poverty. 2020 Jul 20;9(1):99.
3. Cui N, Zou X, Xu L. Preliminary CT findings of coronavirus disease 2019 (COVID-19). Clinical imaging. 2020 Sep;65:124-32.
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020 Feb 15;395(10223):497-506.
5. Jamwal S, Gautam A, Elsworth J, Kumar M, Chawla R, Kumar P. An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic. Life sciences. 2020 Jul 17;257:118105.
6. Arachchillage DRJ, Laffan M. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis : JTH. 2020 May;18(5):1233-4.
7. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of thrombosis and haemostasis : JTH. 2020 May;18(5):1094-9.
8. Chen ZR, Zhou Y, Liu J, Peng HW, Zhou J, Zhong HL, et al. Pharmacotherapics Advice in Guidelines for COVID-19. Frontiers in pharmacology. 2020;11:950.
9. AIFA. Farmaci utilizzabili per il trattamento della malattia COVID-19. Available on-line: https://wwwaifagovit/aggiornamento-sui-farmaci-utilizzabili-per-il-trattamento-della-malattia-covid19 Last accessed: 04 August 2020. 2020.
10. Rossotti R, Travi G, Ughi N, Corradin M, Baiguera C, Fumagalli R, et al. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis. The Journal of infection. 2020 Jul 8.
11. Vinetz JM. Lack of efficacy of hydroxychloroquine in covid-19. BMJ (Clinical research ed). 2020 May 19;369:m2018.
12. AIFA. Idrossiclorochina nella terapia dei pazienti adulti con COVID-19. Available on-line: https://wwwaifagovit/documents/20142/1123276/idrossiclorochina_22072020pdf/764add8f-f08f-0e26-df75-952986e54b8b Last accessed: 04 August 2020. 2020.
13. AIFA. Darunavir/cobicistat nella terapia dei pazienti adulti con COVID-19. Available on-line: https://wwwaifagovit/documents/20142/1123276/darunavir_cobicistat_17072020pdf/6e34d1cf-9d14-4e01-8229-6467de2da082 Last accessed: 04 August 2020. 2020.
14. AIFA. Lopinavir/ritonavir nella terapia dei pazienti adulti con COVID-19. Available on-line: https://wwwaifagovit/documents/20142/1123276/lopinavir_ritonavir_17072020pdf/ab9e07d8-585b-6eda-0007-a8f3d1e175c4 Last accessed: 04 August 2020. 2020.
15. Sun J, Deng X, Chen X, Huang J, Huang S, Li Y, et al. Incidence of Adverse Drug Reactions in COVID-19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System. Clinical pharmacology and therapeutics. 2020 Apr 23.
16. Tuccori M, Convertino I, Ferraro S, Cappello E, Valdiserra G, Focosi D, et al. The Impact of the COVID-19 ”Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance. Drug Saf. 2020 Aug;43(8):699-709.
17. Mazzitello C, Esposito S, De Francesco AE, Capuano A, Russo E, De Sarro G. Pharmacovigilance in Italy: An overview. Journal of pharmacology & pharmacotherapeutics. 2013 Dec;4(Suppl 1):S20-8.
18. Lombardi N, Crescioli G, Bettiol A, Marconi E, Vitiello A, Bonaiuti R, et al. Characterization of serious adverse drug reactions as cause of emergency department visit in children: a 5-years active pharmacovigilance study. BMC pharmacology & toxicology. 2018 Apr 16;19(1):16.
19. Lombardi N, Crescioli G, Bettiol A, Tuccori M, Rossi M, Bonaiuti R, et al. Vaccines Safety in Children and in General Population: A Pharmacovigilance Study on Adverse Events Following Anti-Infective Vaccination in Italy. Frontiers in pharmacology. 2019;10:948.
20. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clinical pharmacology and therapeutics. 1981 Aug;30(2):239-45.
21. Drugs.com. Drug Interactions Checker. Available on-line: https://wwwdrugscom/interaction/list/?drug_list= Last accessed: 04 August 2020.
22. 2.0 M. Drug Interactions. Available on-line: https://wwwmicromedexsolutionscom/micromedex2/4340/WebHelp/Tools/Interactions/Drug_Interactions_severity_definitionshtm Last accessed: 04 August 2020. 2013.
23. Lombardi N, Bettiol A, Crescioli G, Ravaldi C, Bonaiuti R, Venegoni M, et al. Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments. Internal and emergency medicine. 2020 Apr 24.
24. Lombardi N, Crescioli G, Bettiol A, Tuccori M, Capuano A, Bonaiuti R, et al. Italian Emergency Department Visits and Hospitalizations for Outpatients’ Adverse Drug Events: 12-Year Active Pharmacovigilance Surveillance (The MEREAFaPS Study). Frontiers in pharmacology. 2020;11:412.
25. Hult S, Sartori D, Bergvall T, Hedfors Vidlin S, Grundmark B, Ellenius J, et al. A Feasibility Study of Drug-Drug Interaction Signal Detection in Regular Pharmacovigilance. Drug Saf. 2020 Aug;43(8):775-85.
26. Laurence L. Brunton BAC, Bjorn C. Knollman. Quinolines and related compounds. In: Brunton LL, editor. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, Twelfth Edition 12th Edition. New York: McGraw-Hill Companies; 2011. p. Chapter 49; pages 1270-2.
27. Venisse N. Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. Fundamental & clinical pharmacology. 2020 Jul 2.
28. Kelly M, O’Connor R, Townsend L, Coghlan M, Relihan E, Moriarty M, et al. Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin. British journal of clinical pharmacology. 2020 Jul 20.
29. Lu ZK, Yuan J, Li M, Sutton SS, Rao GA, Jacob S, et al. Cardiac risks associated with antibiotics: azithromycin and levofloxacin. Expert opinion on drug safety. 2015 Feb;14(2):295-303.
30. EMA. Kaletra - Annex I - Summary of product characteristics. Available on-line: https://wwwemaeuropaeu/en/documents/product-information/kaletra-epar-product-information_enpdf Last accessed: 04 August 2020.
31. EMA. Prezista - Annex I - Summary of product characteristics. Available on-line: https://wwwemaeuropaeu/en/documents/product-information/prezista-epar-product-information_enpdf Last accessed: 04 August 2020.
32. Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. TheScientificWorldJournal. 2012;2012:212178.
33. Rajkumar RP. COVID-19 and mental health: A review of the existing literature. Asian journal of psychiatry. 2020 Apr 10;52:102066.
34. Tandon R. The COVID-19 pandemic, personal reflections on editorial responsibility. Asian journal of psychiatry. 2020 Apr;50:102100.
35. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. The lancet Psychiatry. 2020 Jul;7(7):611-27.
36. AIFA. Zitromax - Riassunto delle caratteristiche del prodotto. Available on-line: https://farmaciagenziafarmacogovit/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000040_027860_RCPpdf&retry=0&sys=m0b1l3 Last accessed: 04 August 2020.
37. EMA. Relzosta - Annex I - Summary of product characteristics. Available on-line: https://wwwemaeuropaeu/en/documents/product-information/rezolsta-epar-product-information_enpdf Last accessed: 04 August 2020.
38. EMA. Roactemra - Annex I - Summary of product characteristics. Available on-line: https://wwwemaeuropaeu/en/documents/product-information/roactemra-epar-product-information_enpdf Last accessed: 04 August 2020.
39. Das EM, Mohan D. Chloroquine-related depression. Indian J Psychiatry. 1981 Apr;23(2):184-5.
40. Lovestone S. Chloroquine-induced mania. The British journal of psychiatry : the journal of mental science. 1991 Jul;159:164-5.
41. Bogaczewicz A, Sobow T, Bogaczewicz J, Bienkowski P, Kowalski J, Wozniacka A. Chloroquine-induced subacute paranoid-like disorder as a complication of dermatological treatment. International journal of dermatology. 2016 Dec;55(12):1378-80.
42. Bogaczewicz J, Sobow T, Bogaczewicz A, Robak E, Bienkowski P, Sysa-Jedrzejowska A, et al. Exacerbations of bipolar disorder triggered by chloroquine in systemic lupus erythematosus–a case report. Lupus. 2014 Feb;23(2):188-93.
43. Emmanuel S, Ostlundh L. Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic. Asian journal of psychiatry. 2020 Jun 20;54:102203.
44. Bitta MA, Kariuki SM, Mwita C, Gwer S, Mwai L, Newton C. Antimalarial drugs and the prevalence of mental and neurological manifestations: A systematic review and meta-analysis. Wellcome open research. 2017;2:13.
45. Sato K, Mano T, Iwata A, Toda T. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database. Bioscience trends. 2020 May 21;14(2):139-43.
46. Mascolo A, Berrino PM, Gareri P, Castagna A, Capuano A, Manzo C, et al. Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article. Inflammopharmacology. 2018 Oct;26(5):1141-9.
47. Turjanski N. LGG. Psychiatric side-effects of medications: recent developments. Advances in Psychiatric Treatment. 2005;11:58-70.
48. Winston A, Fatkenheuer G, Arribas J, Hill A, van Delft Y, Moecklinghoff C. Neuropsychiatric adverse events with ritonavir-boosted darunavir monotherapy in HIV-infected individuals: a randomised prospective study. HIV clinical trials. 2010 May-Jun;11(3):163-9.
49. Pfefferbaum B, North CS. Mental Health and the Covid-19 Pandemic. The New England journal of medicine. 2020 Aug 6;383(6):510-2.
50. Ravaldi C, Wilson A, Ricca V, Homer C, Vannacci A. Pregnant women voice their concerns and birth expectations during the COVID-19 pandemic in Italy. Women and birth : journal of the Australian College of Midwives. 2020 Jul 13.
51. Matvienko-Sikar K, Meedya S, Ravaldi C. Perinatal mental health during the COVID-19 pandemic. Women and birth : journal of the Australian College of Midwives. 2020 Jul;33(4):309-10.
52. FDA. PLAQUENIL® HYDROXYCHLOROQUINE SULFATE, USP. Available on-line: https://wwwaccessdatafdagov/drugsatfda_docs/label/2007/009768s041lblpdf Last accessed: 04 Agust 2020.
53. Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut. 2020 Jun;69(6):997-1001.
Table 1. Indication of use and mechanism of action of principal SARS-CoV-2 medications in Italy.